2014年6月
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study
HEPATO-GASTROENTEROLOGY
- 巻
- 61
- 号
- 132
- 開始ページ
- 1008
- 終了ページ
- 1013
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.5754/hge14154
- 出版者・発行元
- H G E UPDATE MEDICAL PUBLISHING S A
Background/Aims: To determine the effect of the pyridoxine for prevention of hand- foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine. Methodology: Colorectal cancer patients scheduled for capecitabine chemotherapy as adjuvant setting were randomly assigned to with or without concurrent oral pyridoxine (60 mg/d) groups. Patients were monitored whether being a development of National Cancer Institute Common Toxicity Criteria grade 2 or worse HFS until chemotherapy ended. Results: Sixty patients were enrolled in this study. Relative dose intensity was 89.5% in total. The median number of chemotherapy cycles to grade 2 or worse HFS was four in both groups. Grade 2 or worse HFS developed in 18 (60.0%) of 30 control patients and in 18 (60.0%) of 30 pyridoxine patients. The cumulative dose of capecitabine to grade 2 or worse HFS I was not different between the two groups. Conclusions: Pyridoxine is not effective in prevention of capecitabine-associated HFS.
- リンク情報
- ID情報
-
- DOI : 10.5754/hge14154
- ISSN : 0172-6390
- PubMed ID : 26158157
- Web of Science ID : WOS:000363913800022